Veteran Ventures Capital invests in biomaterials science pioneer Cambium

Daniela Castillo Monagas

Veteran Ventures Capital (VVC), a leading investor in national security technologies, has announced a strategic investment in Cambium, a next-generation defense company. Cambium utilizes a molecule-to-machine approach to re-engineer defense products, significantly improving manufacturability and performance.

Cambium’s advanced biomaterials offer exceptional thermal stability and fire resistance, ideal for various DoD applications. This technology plays a crucial role in protecting critical assets, from hardening UAVs to safeguarding payloads during hypersonic flight.

VVC’s investment will accelerate Cambium’s development and deployment of biomaterial technologies. This partnership bolsters Cambium’s position as a leader in defense and aerospace innovation.

Cambium’s team comprises seasoned experts from leading companies like SpaceX, Virgin Galactic, and Lockheed Martin. Their combined expertise spans product engineering, technology integration, and biomaterial innovation.

Cambium recently completed a contract with the U.S. Naval Air Warfare Center to develop a next-generation bio-manufactured thermal protection system for drones. This novel system offers superior protection against heat, fire, and aerodynamic stress.

Veteran Ventures joined 8VC, GSBackers, and other prominent investors in supporting Cambium’s mission to revolutionize defense technology. This investment marks a significant step in securing the future of U.S. national security through cutting-edge innovation.

TAGGED:
Share This Article